Immunome, Inc. (NASDAQ:IMNM) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Immunome, Inc. (NASDAQ:IMNM) has been assigned a consensus rating of “Moderate Buy” from the eleven ratings firms that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating and ten have given a buy rating to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $31.00.

IMNM has been the subject of several recent analyst reports. Evercore ISI raised their target price on shares of Immunome from $18.00 to $40.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunome in a report on Thursday, January 22nd. Leerink Partners set a $40.00 price target on shares of Immunome in a report on Monday, December 15th. Wall Street Zen raised shares of Immunome from a “sell” rating to a “hold” rating in a report on Saturday, November 22nd. Finally, Wedbush reaffirmed an “outperform” rating and issued a $31.00 price objective on shares of Immunome in a research note on Thursday, January 15th.

Insider Buying and Selling

In related news, Director Isaac Barchas sold 383,200 shares of the stock in a transaction on Monday, December 22nd. The stock was sold at an average price of $21.74, for a total transaction of $8,330,768.00. Following the sale, the director owned 2,031,181 shares of the company’s stock, valued at $44,157,874.94. This trade represents a 15.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Clay B. Siegall bought 4,729 shares of Immunome stock in a transaction on Tuesday, December 30th. The stock was purchased at an average price of $21.15 per share, for a total transaction of $100,018.35. Following the completion of the acquisition, the chief executive officer owned 665,254 shares in the company, valued at $14,070,122.10. This represents a 0.72% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired 68,518 shares of company stock worth $1,453,958 in the last three months. Corporate insiders own 7.69% of the company’s stock.

Institutional Trading of Immunome

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in shares of Immunome by 23.4% during the fourth quarter. Vanguard Group Inc. now owns 6,038,414 shares of the company’s stock worth $129,705,000 after purchasing an additional 1,144,788 shares during the last quarter. Principal Financial Group Inc. boosted its position in shares of Immunome by 222.3% in the third quarter. Principal Financial Group Inc. now owns 1,104,938 shares of the company’s stock worth $12,939,000 after acquiring an additional 762,147 shares during the last quarter. Nan Fung Trinity HK Ltd. acquired a new position in Immunome during the second quarter worth approximately $5,104,000. Candriam S.C.A. boosted its holdings in shares of Immunome by 170.2% in the 3rd quarter. Candriam S.C.A. now owns 859,527 shares of the company’s stock valued at $10,065,000 after purchasing an additional 541,441 shares during the last quarter. Finally, Pivotal bioVenture Partners Investment Advisor LLC purchased a new position in shares of Immunome in the 3rd quarter worth $5,884,000. 44.58% of the stock is owned by hedge funds and other institutional investors.

Immunome Stock Performance

Shares of Immunome stock opened at $25.07 on Friday. The company’s fifty day moving average is $21.18 and its two-hundred day moving average is $15.38. Immunome has a 1 year low of $5.15 and a 1 year high of $26.63. The company has a market capitalization of $2.30 billion, a P/E ratio of -8.50 and a beta of 2.22.

Immunome (NASDAQ:IMNM) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.08). Immunome had a negative return on equity of 76.50% and a negative net margin of 1,687.08%. As a group, equities analysts expect that Immunome will post -2.21 earnings per share for the current year.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.